
Thirty Day Readmission Rates for Acute Asthma Exacerbation in a Community based Hospital Setting



Campuses of UH Regional Hospitals

Scott Stiles, D.O.3, Christopher Wood, D.O.3, Julie Alderson, D.O.3, Priya Varma, D.O.3, Hao Luong, D.O.3, Lauren Albrecht MLS, ASCP4, Monica Sandhu, D.O.1,

Brian. Peppers D.O., PhD.¹, Robert W. Hostoffer Jr., D.O.¹⁻³






INTRODUCTION

Asthma is a serious health concern in the United States
affecting 1 in 12 adults, resulting in 439,000 asthma-related
hospitalizations in 2013 alone. To date, there is a paucity of
data determining the thirty day asthma re-hospitalization rates
in US based community hospitals in patients discharged on
combined inhaled corticosteroid (ICS) and oral corticosteroid
(OCS), OCS or ICS alone. We hypothesize that the rehospitalization rates in the combined treatment populations
will be relatively low.

Components of Severity		Classification of Asthma Severity (≥12 years of age)					
		Intermittent	Persistent				
			Mild	Moderate	Severe		
Impairment	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day		
Normal FEV ₊ /FVC: 8-19 yr 85% 20-39 yr 80% 40-59 yr 75% 60-80 yr 70%	Nighttime awakenings	≤2x/month 3-4x/month		>1x/week but not nightly	Often 7x/week		
	Short-acting beta ₂ - agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not daily, and not more than 1x on any day	Daily	Several times per day		
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited		
	Lung function	•Normal FEV, between exacerbations •FEV, >80% predicted •FEV,/FVC normal	•FEV ₁ >80% predicted •FEV ₁ /FVC normal	•FEV ₁ >60% but <80% predicted •FEV ₁ /FVC reduced 5%	*FEV ₁ <60% predicted *FEV ₁ /FVC reduced >5%		
	Exacerbations requiring oral systemic corticosteroids	0-1/year (see note)	≥ 2/year(see note)				
Risk		Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity category. Relative annual risk of exacerbations may be related to FEV ₁ .					
Recommended Step for Initiating Treatment		Step 1	Step 2	Step 3 and consider short course	Step 4 or 5 of oral systemic corticosteroids		
		In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly					



	WILTHOUS			
Type of Study:	- Retrospective			
Inclusion Criteria:	 Admission to UH Regional or UH Geauga for an acute exacerbation of asthma Between Jan 2011 - Dec 2015 			
Exclusion Criteria:	- COPD - Fever >38°C - >15 pack year history - Pregnancy/Lactation - Severe mental illness (past or present) - Diabetes or Peptic ulcer disease - Abnormalities on X-ray - Extra-pulmonary infection			

MFTHODS

RESULTS

- 373 admissions between Jan 2011 & Dec 2015
- 319 between 18-65 years-old (mean age 44.98)
- 167 included after applying exclusion criteria

• Sex - Female: 67.1% - Male: 32.9%

• Ethnicity - African American 65.9%

- White 33.5%

- Asian 0.6%

• Hospitalizations in past year - Mean: 0.83 (min 0; max 8)

• ICS prior to admission - Prior ICS 50.3%

• Discharge regimen - Combined: 68.3%

- OCS alone: 23.4% - ICS alone: 6.6%

• LABA at discharge - 60.7%

RESULTS (Continuea)								
	ocs	Combined	ICS	None	N			
Total Admissions	39 (23.5%)	114 (68.3%)	11 (6.59%)	3 (1.80%)	167 (100%)			
No Readmission	38 (23.7%)	108 (67.5%)	11 (6.9%)	3 (1.9%)	160 (100%)			
Readmission <30 days	1 (14.3%)	6 (87.7%)	0 (0.0%)	0 (0.0%)	7 (100%)			
% of Readmissions	2.56%	5.26%	0%	0%	4.19%			
Admissions in past year	1.0	4.1	-	-				

P = 0.754

CONCLUSION

- The data showed the thirty-day readmission rate of patients discharged on combined therapy (5.26%) was higher, although not significantly (p=0.754), compared to that for patients discharged on OCS alone (2.56%).
- Our data suggests that there is no difference in 30 day readmission rates comparing discharge medications of OCS versus OCS plus ICS in community based hospital settings.
- Our data also suggests that less expensive discharge medications may be sufficient in decreasing readmission rates and decreasing patient's financial burden in community based hospital settings.
- We are currently in the process of revising the data to account for asthma severity. We are also
 increasing our sample size by adding patients from other hospitals within the UH system.

Disclosure of Commercial Support and Relevant Financial Interests: Nothing to report